Pushkal Garg

9.3k total citations · 3 hit papers
35 papers, 3.2k citations indexed

About

Pushkal Garg is a scholar working on Transplantation, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Pushkal Garg has authored 35 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Transplantation, 10 papers in Public Health, Environmental and Occupational Health and 6 papers in Molecular Biology. Recurrent topics in Pushkal Garg's work include Renal Transplantation Outcomes and Treatments (12 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Pregnancy and Medication Impact (5 papers). Pushkal Garg is often cited by papers focused on Renal Transplantation Outcomes and Treatments (12 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Pregnancy and Medication Impact (5 papers). Pushkal Garg collaborates with scholars based in United States, Spain and France. Pushkal Garg's co-authors include Neil R. Powe, Flavio Vincenti, G. Russo, Marie Diener‐West, Yves Vanrenterghem, Christian P. Larsen, B Charpentier, Barbara A. Bresnahan, Lionel Rostaing and Lin Chen and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Pushkal Garg

34 papers receiving 3.1k citations

Hit Papers

A Phase III Study of Belatacept‐based Immunosuppression R... 2010 2026 2015 2020 2010 2010 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
    2010 690 citations Flavio Vincenti, B Charpentier et al. American Journal of Transplantation profile →
  2. Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
    2010 424 citations Antoine Dürrbach, Flavio Vincenti et al. American Journal of Transplantation profile →
  3. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
    2019 316 citations Scott D. Solomon, David Adams et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pushkal Garg United States 22 1.3k 700 650 591 470 35 3.2k
Paul Harden United Kingdom 30 757 0.6× 594 0.8× 473 0.7× 404 0.7× 863 1.8× 96 3.4k
John J. Friedewald United States 33 2.4k 1.8× 1.8k 2.5× 305 0.5× 1.3k 2.2× 562 1.2× 125 4.1k
John F. Neylan United States 30 3.2k 2.4× 2.0k 2.9× 372 0.6× 976 1.7× 738 1.6× 59 5.2k
Lynt B. Johnson United States 42 1.0k 0.8× 2.9k 4.1× 542 0.8× 1.4k 2.3× 806 1.7× 132 5.4k
David A. Goldfarb United States 43 2.1k 1.6× 2.8k 4.1× 837 1.3× 1.8k 3.1× 356 0.8× 190 6.0k
David K. Klassen United States 37 2.2k 1.6× 1.6k 2.3× 106 0.2× 1.1k 1.9× 378 0.8× 133 4.4k
David W. Gjertson United States 29 2.2k 1.6× 2.1k 3.0× 167 0.3× 1.6k 2.7× 326 0.7× 69 3.9k
Kenneth J. Woodside United States 24 440 0.3× 673 1.0× 188 0.3× 204 0.3× 245 0.5× 109 1.9k
Maureen McBride United States 37 2.5k 1.8× 3.0k 4.2× 127 0.2× 2.3k 4.0× 657 1.4× 95 5.3k
Edward A. Copelan United States 31 263 0.2× 247 0.4× 878 1.4× 1.3k 2.2× 352 0.7× 194 5.7k

Countries citing papers authored by Pushkal Garg

Since Specialization
Citations

This map shows the geographic impact of Pushkal Garg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pushkal Garg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pushkal Garg more than expected).

Fields of papers citing papers by Pushkal Garg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pushkal Garg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pushkal Garg. The network helps show where Pushkal Garg may publish in the future.

Co-authorship network of co-authors of Pushkal Garg

This figure shows the co-authorship network connecting the top 25 collaborators of Pushkal Garg. A scholar is included among the top collaborators of Pushkal Garg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pushkal Garg. Pushkal Garg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gayà, Anna, Talha Munir, Álvaro Urbano-Ispizúa, et al.. (2023). Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. SHILAP Revista de lepidopterología. 4(3). 612–624. 13 indexed citations
2.
Judge, Daniel P., Arnt V. Kristen, Martha Grogan, et al.. (2020). Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy. 34(3). 357–370. 80 indexed citations
3.
Judge, Daniel P., Arnt V. Kristen, Martha Grogan, et al.. (2020). Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy. 34(6). 889–889. 49 indexed citations
4.
Habtemariam, Bahru, Verena Karsten, Husain Attarwala, et al.. (2020). Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clinical Pharmacology & Therapeutics. 109(2). 372–382. 130 indexed citations
5.
Solomon, Scott D., David Adams, Arnt V. Kristen, et al.. (2019). Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 139(4). 431–443. 316 indexed citations breakdown →
6.
Ferguson, R M, J.M. Grinyó, Flavio Vincenti, et al.. (2010). Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant Recipients. American Journal of Transplantation. 11(1). 66–76. 153 indexed citations
7.
Vincenti, Flavio, B Charpentier, Yves Vanrenterghem, et al.. (2010). A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). American Journal of Transplantation. 10(3). 535–546. 690 indexed citations breakdown →
8.
Dürrbach, Antoine, Christian P. Larsen, Yves Vanrenterghem, et al.. (2009). Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in ECD Kidney Transplants (BENEFIT-EXT Study). American Journal of Transplantation. 9. 199–199. 4 indexed citations
9.
10.
Dy, Sydney M., Pushkal Garg, Dorothy Nyberg, et al.. (2003). . Medical Care. 41(5). 637–648. 4 indexed citations
11.
Dy, Sydney M., Pushkal Garg, Dorothy Nyberg, et al.. (2003). Are Critical Pathways Effective for Reducing Postoperative Length of Stay?. Medical Care. 41(5). 637–648. 41 indexed citations
12.
Kochar, D K, R.P. Agrawal, Avni Vyas, et al.. (2003). Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM. 97(1). 33–38. 93 indexed citations
13.
Garg, Pushkal, Mary Beth Landrum, Sharon‐Lise T. Normand, et al.. (2002). Understanding Individual and Small Area Variation in the Underuse of Coronary Angiography Following Acute Myocardial Infarction. Medical Care. 40(7). 614–626. 36 indexed citations
14.
Garg, Pushkal, Marie Diener‐West, & Neil R. Powe. (2001). Income-based disparities in outcomes for patients with chronic kidney disease. Seminars in Nephrology. 21(4). 377–385. 49 indexed citations
15.
Guadagnoli, Edward, Mary Beth Landrum, Sharon‐Lise T. Normand, et al.. (2001). Impact of Underuse, Overuse, and Discretionary Use on Geographic Variation in the Use of Coronary Angiography After Acute Myocardial Infarction. Medical Care. 39(5). 446–458. 43 indexed citations
16.
Garg, Pushkal, Marie Diener‐West, & Neil R. Powe. (2001). Reducing racial disparities in transplant activation:Whom should we target?. American Journal of Kidney Diseases. 37(5). 921–931. 47 indexed citations
17.
Garg, Pushkal, Susan L. Furth, Barbara A. Fivush, & Neil R. Powe. (2000). Impact of Gender on Access to the Renal Transplant Waiting List for Pediatric and Adult Patients. Journal of the American Society of Nephrology. 11(5). 958–964. 77 indexed citations
18.
Garg, Pushkal, Kevin D. Frick, Marie Diener‐West, & Neil R. Powe. (1999). Effect of the Ownership of Dialysis Facilities on Patients' Survival and Referral for Transplantation. New England Journal of Medicine. 341(22). 1653–1660. 177 indexed citations
19.
Garg, Pushkal. (1998). Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstetrics and Gynecology. 92(3). 472–479. 136 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Harden Breakdown of academic impact, for papers by John J. Friedewald Breakdown of academic impact, for papers by John F. Neylan Breakdown of academic impact, for papers by Lynt B. Johnson Breakdown of academic impact, for papers by David A. Goldfarb Breakdown of academic impact, for papers by David K. Klassen Breakdown of academic impact, for papers by David W. Gjertson Breakdown of academic impact, for papers by Kenneth J. Woodside Breakdown of academic impact, for papers by Maureen McBride Breakdown of academic impact, for papers by Edward A. Copelan
Rankless by CCL
2026